Warfarin Dose Adjustment for Antiphospholipid Syndrome

Target INR for Antiphospholipid Syndrome

• The target INR for patients with antiphospholipid syndrome should be maintained at 2.0-3.0, indicating that an INR of 1.9 falls just below the therapeutic range, suggesting subtherapeutic anticoagulation 1

Specific Dose Adjustment Algorithm

• For an INR of 1.6-1.9, the weekly warfarin dose should be increased by 10%, which can be calculated as 35 mg × 1.10 = 38.5 mg per week, and practically achieved by alternating 5 mg and 6 mg doses 1

Monitoring Strategy

• Recheck INR within 1-2 weeks after dose adjustment to assess response, and consider continuing the current dose and retesting within 1-2 weeks for a single INR ≤0.5 below therapeutic range in previously stable patients 1
• In antiphospholipid syndrome, a high-risk thrombotic condition, more aggressive management is warranted even for minor INR deviations 2

Critical Considerations for Antiphospholipid Syndrome

• Antiphospholipid syndrome represents a high thromboembolic risk condition with recurrent thrombosis potential, requiring meticulous INR control 2
• The risk of recurrent thromboembolism in antiphospholipid syndrome justifies prompt dose adjustment rather than watchful waiting 2

Common Pitfalls to Avoid

• Do not ignore an INR of 1.9 in antiphospholipid syndrome patients, as these patients have higher thrombotic risk than typical VTE patients 2
• Avoid making excessive dose changes (>15% weekly) for minor INR deviations, as this can cause INR instability 1
• Investigate potential causes of subtherapeutic INR, such as medication non-adherence, drug interactions, or new medications 1